VERY FAVORABLE RISK/REWARD HERE BUY WITH BOTH FISTS
At wells fargo, very bullish statements on pipeline and that manta has built up a huge inventory ready for immediate release upon copaxone approval as FDA was rejecting desperate attempts by teva to delay with stall tactics and tainted studies. ((((((BUYING WITH BOTH FISTS))))). Laughing at shorts who argue risk here at $11 when MNTA already took a 50% haircut on old issues they continue to bring up in a feeble attempt to cast doubt on the future of MNTA which has multiple catalysts going forward
Based on a recent Zacks writeup (8/29/14) ("Momenta expects the generic version of Copaxone to be available in the first quarter of 2017") why would they tie up inventory assets for such a long period?
I'll assume this is a legit question - Momenta plans to sell basic, generic Copaxone somewhere between "immediately" and May 2015 ( when Teva's patent expires); it also plans to sell the more advanced formulation of Copaxone when the patent expires in early 2017.
The judge rejected Momenta/Sandoz and Mylan/Natco’s claims that the COPAXONE® patents are invalid and unenforceable and found that the purported generic versions of COPAXONE® for which Momenta/Sandoz and Mylan/Natco seek Food and Drug Administration (FDA) approval infringe those patents. This ruling should prevent the FDA from approving, and the defendants from selling their purported generic versions of COPAXONE® in the U.S. until the Orange Book patents expire on May 24, 2014. As a result of this ruling, Teva also believes that the defendants will be enjoined from selling their products until the process patent expires on September 1, 2015. Furthermore, any purported generic version of COPAXONE® would need to obtain FDA approval prior to being made available to the public. At this point, it is unclear what the requirements would be for approval of a purported generic synthetic peptide.
Court decided in mnta's favor and teva is on its hands and knees hoping for a long shot US Supreme Court reversal of that appellate decision, nevertheless MNTA has built up a huge inventory ready to release generic copaxone this month